Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 and -2 in Type 2 Diabetes: Effect of 1 year’s cardiovascular risk reduction therapy

Brief Reports

Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 and -2 in Type 2 Diabetes

From the Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, U.K

Address correspondence and reprint requests to Professor Gregory Y.H. Lip, City Hospital, University Department of Medicine, Haemostasis Thrombosis and Vascular Biology Unit, Birmingham B18 7QH, U.K. E-mail: g.y.h.lip{at}bham.ac.uk

Diabetes Care 2004 Aug; 27(8): 2049-2051. https://doi.org/10.2337/diacare.27.8.2049

Table 1—

Baseline characteristics of study population

	Patients	Control subjects	P
n	86	63	—
Age (years)	68 ± 6	66 ± 10	0.115*
Male	67	53	0.079†
Cardiovascular disease	46	—	—
Current smokers	16	12	0.575†
Drug therapy
ACE inhibitor	100	—	—
Aspirin	42	—	—
Statin	24	—	—
Sulphonylurea	100	—	—
Metformin	43	—	—
Glitazone	3	—	—
BMI (kg/m²)	28 ± 4	27 ± 4	0.575*
Systolic blood pressure (mmHg)	139 ± 19	131 ± 13	0.006*
Diastolic blood pressure (mmHg)	77 ± 10	76 ± 10	0.578*
Cholesterol (mmol/l)	5.0 ± 1.1	5.3 ± 1.1	0.065*
HDL (mmol/l)	1.3 ± 0.3	1.6 ± 0.4	<0.0001*
Triglycerides (mmol/l)	1.6 (1.2–2.6)	1.5 (0.8–2.2)	0.146‡
HbA_1c (%)	7.4 (6.6–8.2)	5.4 (5.2–5.6)	<0.0001‡
TIMP-2 (ng/ml)	143 (120–160)	110 (93–143)	<0.0001‡
MMP-9 (ng/ml)	65 (48–81)	56 (45–75)	0.028‡
TIMP-1 (ng/ml)	397 (300–496)	280 (225–305)	<0.0001‡

Data are means ± SD, median (interquartile range), or percent.
*
↵* Student’s t test
†
↵† χ² analysis
‡
↵‡ Mann-Whitney U test. To convert cholesterol and HDL from mmol to mg/dl multiply by 38.6; to convert triglycerides multiply by 88.5